Journal of Medical Economics

Article	Citations
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study	97
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in	79
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsych	54
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing	50
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study	38
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis	37
The economic burden of systemic lupus erythematosus in Taiwan	34
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs	32
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	32
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States	31
Budget impact analysis of cenobamate, a novel adjunctive therapy for the treatment of drug resistant focal onset seizures, from the Belgian healthcare payer perspective	31
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	30
Challenges in health economics research: insights from real-world examples	27
Economic review of point-of-care EEG	27
Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries	27
Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity	26
The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington’s disease	23
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment	22
Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom	21
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm	21
Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective	20
Effects of liposomal bupivacaine (LB) and provider experience with LB on service utilization, clinical outcomes, and Medicare expenditures among fee-for-service (FFS) beneficiaries	19
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspective	19
Utilities associated with stoma-related complications: peristomal skin complications and leakages	19
Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries	18

Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world	17
Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder	16
Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin	16
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland	15
The indirect costs of vaccine-preventable cancer mortality in the Middle East and North Africa (MENA)	15
Inflation-adjusted analysis of ICER’s Unsupported Price Increase reports: contextualizing drug spending changes	15
The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective	15
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in F	15
A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States	14
Estimation of the utilities of attributes of intravenous iron infusion treatment for patients with iron-deficiency anemia: a conjoint analysis in Japan	14
Cost-effectiveness of intravenous resuscitation fluids in sepsis patients: a patient-level data analysis in Jordan	14
Cost-effectiveness of volume computed tomography in lung cancer screening: a cohort simulation based on Nelson study outcomes	14
Economic burden of respiratory syncytial virus in adults in Germany – a health claims analysis between 2015 and 2018	13
Evaluating cost-effectiveness of PFO management strategies: closure with Cardioform vs. Amplatzer, and treatment with medical therapy alone, for secondary stroke prevention	13
Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer	13
Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adhe	13
Gastric cancer in Spain: evaluating productivity loss and economic impact	13
Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective	13
Cost-effectiveness analysis of intradiscal condoliase injection vs. surgical or conservative treatment for lumbar disc herniation	13
An evaluation of the best practices and barriers for the Nagasaki acute myocardial infarction secondary prevention clinical pathway	13
Carbon footprint and associated costs of asthma exacerbation care among UK adults	13
Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS	12
Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China	12
The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective	12
Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan	12
Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States	12
A review of the cost-effectiveness of genetic testing for germline variants in familial cancer	11
Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison	11
Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands	11
Economic impact associated with dronedarone use in patients with atrial fibrillation	11
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data	11
A cost-consequence analysis comparing three cardiac ablation strategies for the treatment of paroxysmal atrial fibrillation	11
Correction	10
Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany	10
A prospective cohort study estimating total pre-surgical healthcare costs before and two-year total societal costs after resective brain surgery, and quality of life of patients with drug-resistant ep	10
Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England	10
Economic impact analysis of a minimally invasive temperature-controlled radiofrequency device versus nasal surgery for the treatment of nasal airway obstruction in the United States	10
Correction	10
Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait	10
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain	10
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective	9
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada	9
Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthca	9
Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain	9
Economic burden of COVID-19 for employers and employees in the United States	9
Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis	9
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemoth	9
Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden – A pilot study comparing extrapolated and observed life-years gained	9
Benefits of MR-proADM-guided decision-making in the emergency department: clinical and economic evaluation in Italy, Germany, Spain, and the UK	9
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1	9

Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs	9
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia	9
Cost effectiveness of implantable cardioverter defibrillators for 1.5 primary prevention of sudden cardiac arrest in China: an analysis from the Improve SCA study	8
Comparison of utilization and cost of healthcare services and pharmacotherapy following implantation of vagus nerve stimulation vs. responsive neurostimulation or deep b	8
Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-Medicare study	8
Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction Act	8
The societal economic value of COVID-19 vaccines in the United States	8
Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches	8
Economic evaluations of exome and genome sequencing in pediatric genetics: considerations towards a consensus strategy	8
Correction	8
Addendum	8
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison	8
The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study	8
Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US	8
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants	8
Promoting equality in utilization of basic public health services in China: the role of the family doctor contract service	8
The economic burden of recurrence in elderly patients with completely resected, stage IIB/IIC or III melanoma: an analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database	8
Journal of Medical Economics in review: the best of 2021	8
Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results	8
Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission for major depressive disorder	8
Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam – findings from a modelling study assessing an EMPA-KIDNEY eligible population	8
Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible	7
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	7
Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis	7
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait	7
Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States	7
The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis	7
Racial variation in healthcare resource utilization and expenditures in knee/hip osteoarthritis patients: a retrospective analysis of a Medicaid population	7
Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China	7
Moving preinduction cervical ripening to a lower acuity inpatient setting using the synthetic hygroscopic cervical dilator: a cost-consequence analysis for the United States	7
Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19	6
Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy	6
Burden and indirect cost of vaccine-preventable cancer mortality in Europe	6
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system persp	6
Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021	6
Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation	6
Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics	6
The economic burden of Ebola virus disease: a review and recommendations for analysis	6
U.S. payer budget impact of using an AI-augmented cancer risk discrimination digital histopathology platform to identify high-risk of recurrence in women with early-stage invasive breast cancer	6
Willingness to pay for the effect of SARS-CoV-2 antivirals in preventing COVID-19 transmission to others in the Japanese population	6
Impact of rifaximin use following an initial overt hepatic encephalopathy hospitalization on rehospitalization and costs	6
Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States	6
Advancing towards a worldwide healthcare system in the post-COVID-19 era: benefits and barriers to international collaboration in healthcare	6
Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States	6
Validation of the IHE type 2 diabetes cohort model in the Japanese clinical setting	6
Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children	6
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan	6
Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid or	6
Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evalu	6
Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan	6
Reply letter to “Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal”	6
Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA	6
Cost impact analysis of novel host-response diagnostic for patients with community-acquired pneumonia in the emergency department	6
Economic option value associated with surgical aortic valve replacement using a novel bioprosthetic and a future transcatheter aortic valve-in-valve procedure	6
Hospital care and medical costs of septic arthritis in Spain: a retrospective multicenter analysis	6
Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s Disease (aPD): demonstration of savings from a societal perspective in the UK	6
Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma	5
Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma	5
The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States	5
Autologous skin cell suspension plus phototherapy in stable vitiligo: findings from a US economic model	5
Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy	5
Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan	5
Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China	5
Cost-effectiveness of TOMAC therapy for medication-refractory restless legs syndrome: an updated analysis based on Extension study data	5
The indirect costs and burden of vaccine-preventable cancers premature mortality in Asia-Pacific countries	5
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands	5
Technical and regulatory challenges of digital health implementation in developing countries	5
Burden of COVID-19 during the omicron predominance in Brazil: a nationwide retrospective database study	5
An Italian cost-utility analysis of 20-valent pneumococcal conjugate vaccine for routine vaccination in infants	5
Place of care and costs associated with acute episodes and remission in bipolar I disorder	5
Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK	5
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US	5
Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer	5
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis	5
Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan	5
Correction	5
Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials	5
Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study	5
Measurement and valuation of the attributes of innovation of healthcare technologies: a systematic review	5
Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study	5

Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galca	5
Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada	5
Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare	5
Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial	5
Cost-effectiveness analysis of HLA-B*13:01 screening for the prevention of co-trimoxazole-induced severe cutaneous adverse reactions among HIV-infected patients in Thailand	5
Reflex single-gene non-invasive prenatal testing is associated with markedly better detection of fetuses affected with single-gene recessive disorders at lower cost	5
A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix in patients diagnosed with non-muscle-invasive bladder cancer in France	5
The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia	5
Using system dynamics modeling approach to strengthen health systems to combat cancer: a systematic literature review	5
Cost-effectiveness of Left Atrial Appendage Closure with WATCHMAN device for non-valvular atrial fibrillation patients in Japan. Are the policy implications big in Japan?	5